These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37726961)

  • 21. Reduced growth velocity from the mid-trimester is associated with placental insufficiency in fetuses born at a normal birthweight.
    Kennedy LM; Tong S; Robinson AJ; Hiscock RJ; Hui L; Dane KM; Middleton AL; Walker SP; MacDonald TM
    BMC Med; 2020 Dec; 18(1):395. PubMed ID: 33357243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Iatrogenic Delivery for Suspected Fetal Growth Restriction and Childhood School Outcomes.
    Selvaratnam RJ; Wallace EM; Wolfe R; Anderson PJ; Davey MA
    JAMA; 2021 Jul; 326(2):145-153. PubMed ID: 34255007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ten-year experience of protocol-based management of small-for-gestational-age fetuses: perinatal outcome in late-pregnancy cases diagnosed after 32 weeks.
    Meler E; Mazarico E; Eixarch E; Gonzalez A; Peguero A; Martinez J; Boada D; Vellvé K; Gomez-Roig MD; Gratacós E; Figueras F
    Ultrasound Obstet Gynecol; 2021 Jan; 57(1):62-69. PubMed ID: 33159370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of heparin on fetal growth restriction].
    Yu YH; Shen LY; Zhong M; Zhang Y; Su GD; Gao YF; Quan S; Zeng L
    Zhonghua Fu Chan Ke Za Zhi; 2004 Dec; 39(12):793-6. PubMed ID: 15733401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of stillbirth, preterm delivery, and fetal growth restriction following exposure in a previous birth: systematic review and meta-analysis.
    Malacova E; Regan A; Nassar N; Raynes-Greenow C; Leonard H; Srinivasjois R; W Shand A; Lavin T; Pereira G
    BJOG; 2018 Jan; 125(2):183-192. PubMed ID: 28856792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction.
    McLaughlin K; Hobson SR; Chandran AR; Agrawal S; Windrim RC; Parks WT; Bowman AW; Sovio U; Smith GC; Kingdom JC
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1145-S1156.e1. PubMed ID: 34461078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of telehealth-integrated antenatal care on pregnancy outcomes in Australia: an interrupted time-series analysis.
    Thirugnanasundralingam K; Davies-Tuck M; Rolnik DL; Reddy M; Mol BW; Hodges R; Palmer KR
    Lancet Digit Health; 2023 Nov; 5(11):e798-e811. PubMed ID: 37890903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship among placenta previa, fetal growth restriction, and preterm delivery: a population-based study.
    Ananth CV; Demissie K; Smulian JC; Vintzileos AM
    Obstet Gynecol; 2001 Aug; 98(2):299-306. PubMed ID: 11506849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neonatal outcomes following early fetal growth restriction: a subgroup analysis of the EVERREST study.
    Lingam I; Okell J; Maksym K; Spencer R; Peebles D; Buquis G; Ambler G; Morsing E; Ley D; Singer D; Tenorio V; Dyer J; Ginsberg Y; Weissbach T; Huertas-Ceballos A; Marlow N; David A;
    Arch Dis Child Fetal Neonatal Ed; 2023 Nov; 108(6):599-606. PubMed ID: 37185272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia.
    Kupferminc M; Rimon E; Many A; Maslovitz S; Lessing JB; Gamzu R
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):123-6. PubMed ID: 21192252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maternal and perinatal outcomes of extreme obesity in pregnancy.
    Crane JM; Murphy P; Burrage L; Hutchens D
    J Obstet Gynaecol Can; 2013 Jul; 35(7):606-611. PubMed ID: 23876637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive role of Doppler indices of cerebral-placental-uterine ratio and umbilico-cerebral ratio for late-onset fetal growth restriction: a prospective cohort study.
    Niroomanesh S; Golshahi F; Hessami K; Saleh M; Salari Z; Sahebdel B; Rahimi-Sharbaf F; Shirazi M; Darabi MH; Mahdavi HF
    J Obstet Gynaecol; 2022 Aug; 42(6):1882-1888. PubMed ID: 35476537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does detection of fetal growth restriction improve neonatal outcomes?
    Selvaratnam RJ; Wallace EM; Treleaven S; Hooper SB; Davis PG; Davey MA
    J Paediatr Child Health; 2021 May; 57(5):677-683. PubMed ID: 33314475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infant outcome after active management of early-onset fetal growth restriction with absent or reversed umbilical artery blood flow.
    Morsing E; Brodszki J; Thuring A; Maršál K
    Ultrasound Obstet Gynecol; 2021 Jun; 57(6):931-941. PubMed ID: 32862450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early- and late-onset selective fetal growth restriction in monochorionic twin pregnancy with expectant management.
    Wang Y; Shi H; Wang X; Yuan P; Wei Y; Zhao Y
    J Gynecol Obstet Hum Reprod; 2022 Apr; 51(4):102314. PubMed ID: 35042000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction.
    Groom KM; David AL
    Am J Obstet Gynecol; 2018 Feb; 218(2S):S829-S840. PubMed ID: 29229321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Doppler ultrasound at time of diagnosis of late-onset fetal growth restriction in predicting adverse perinatal outcome: prospective cohort study.
    Rizzo G; Mappa I; Bitsadze V; Słodki M; Khizroeva J; Makatsariya A; D'Antonio F
    Ultrasound Obstet Gynecol; 2020 Jun; 55(6):793-798. PubMed ID: 31343783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians.
    Vayssière C; Sentilhes L; Ego A; Bernard C; Cambourieu D; Flamant C; Gascoin G; Gaudineau A; Grangé G; Houfflin-Debarge V; Langer B; Malan V; Marcorelles P; Nizard J; Perrotin F; Salomon L; Senat MV; Serry A; Tessier V; Truffert P; Tsatsaris V; Arnaud C; Carbonne B
    Eur J Obstet Gynecol Reprod Biol; 2015 Oct; 193():10-8. PubMed ID: 26207980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction: A Randomized Clinical Trial.
    Pels A; Derks J; Elvan-Taspinar A; van Drongelen J; de Boer M; Duvekot H; van Laar J; van Eyck J; Al-Nasiry S; Sueters M; Post M; Onland W; van Wassenaer-Leemhuis A; Naaktgeboren C; Jakobsen JC; Gluud C; Duijnhoven RG; Lely T; Gordijn S; Ganzevoort W;
    JAMA Netw Open; 2020 Jun; 3(6):e205323. PubMed ID: 32585017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severity of fetal growth restriction stratified according to maternal obesity.
    Tanner LD; Brock And C; Chauhan SP
    J Matern Fetal Neonatal Med; 2022 May; 35(10):1886-1890. PubMed ID: 32482116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.